Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

Charles E. Eberhart, Robert J. Coffey, Aramandla Radhika, Francis M Giardiello, Suzanne Ferrenbach, Raymond N. Dubois

Research output: Contribution to journalArticle

Abstract

Background/Aims: Several clinical, epidemiological, and animal studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) may alter the incidence of colorectal cancer. A likely target for NSAIDs is cyclooxygenase, a key enzyme in arachidonic acid metabolism. Two isoforms of this enzyme have been identified; cyclooxygenase (COX) 1 and COX-2. The present study was undertaken to determine if there is differential expression of these isoforms in colorectal neoplasia, and, if so, at what stage in malignant transformation this occurs. Methods: COX-1 and COX-2 messenger RNA (mRNA) levels were determined by Northern blot analysis of poly(A) + RNA isolated from human colorectal cancers, adenomas, and accompanying normal mucosa. Results: There was a marked increase in COX-2 mRNA levels in 12 of 14 carcinomas (86%) compared with paired normal mucosa. In contrast, there was equivalent intensity of the COX-1 mRNA transcript between the normal mucosa and cancer in all 14 cases. In six pairs of colorectal adenomas and normal mucosa, three showed up-regulation of COX-2 in the adenoma compared with the normal mucosa. Because COX-2 expression is low to undetectable in normal colorectal mucosa, 14 unpaired adenomas were examined for COX-2 expression; a clearly detectable transcript was identified in six (43%). Conclusions: COX-2, but not COX-1, gene expression is markedly elevated in most human colorectal cancers compared with accompanying normal mucosa. Furthermore, COX-2 expression seems to be increased in a subset of adenomas. COX-2 may provide an attractive therapeutic target in colorectal neoplasia.

Original languageEnglish (US)
Pages (from-to)1183-1188
Number of pages6
JournalGastroenterology
Volume107
Issue number4
StatePublished - 1994

Fingerprint

Cyclooxygenase 2
Adenoma
Adenocarcinoma
Up-Regulation
Gene Expression
Mucous Membrane
Cyclooxygenase 1
Colorectal Neoplasms
Messenger RNA
Protein Isoforms
Anti-Inflammatory Agents
Neoplasms
Enzymes
Prostaglandin-Endoperoxide Synthases
Arachidonic Acid
Pharmaceutical Preparations
Northern Blotting
Epidemiologic Studies
Carcinoma
Incidence

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & Dubois, R. N. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107(4), 1183-1188.

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. / Eberhart, Charles E.; Coffey, Robert J.; Radhika, Aramandla; Giardiello, Francis M; Ferrenbach, Suzanne; Dubois, Raymond N.

In: Gastroenterology, Vol. 107, No. 4, 1994, p. 1183-1188.

Research output: Contribution to journalArticle

Eberhart, CE, Coffey, RJ, Radhika, A, Giardiello, FM, Ferrenbach, S & Dubois, RN 1994, 'Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas', Gastroenterology, vol. 107, no. 4, pp. 1183-1188.
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107(4):1183-1188.
Eberhart, Charles E. ; Coffey, Robert J. ; Radhika, Aramandla ; Giardiello, Francis M ; Ferrenbach, Suzanne ; Dubois, Raymond N. / Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. In: Gastroenterology. 1994 ; Vol. 107, No. 4. pp. 1183-1188.
@article{f2d491bbb77944ffa3809d7950507066,
title = "Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas",
abstract = "Background/Aims: Several clinical, epidemiological, and animal studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) may alter the incidence of colorectal cancer. A likely target for NSAIDs is cyclooxygenase, a key enzyme in arachidonic acid metabolism. Two isoforms of this enzyme have been identified; cyclooxygenase (COX) 1 and COX-2. The present study was undertaken to determine if there is differential expression of these isoforms in colorectal neoplasia, and, if so, at what stage in malignant transformation this occurs. Methods: COX-1 and COX-2 messenger RNA (mRNA) levels were determined by Northern blot analysis of poly(A) + RNA isolated from human colorectal cancers, adenomas, and accompanying normal mucosa. Results: There was a marked increase in COX-2 mRNA levels in 12 of 14 carcinomas (86{\%}) compared with paired normal mucosa. In contrast, there was equivalent intensity of the COX-1 mRNA transcript between the normal mucosa and cancer in all 14 cases. In six pairs of colorectal adenomas and normal mucosa, three showed up-regulation of COX-2 in the adenoma compared with the normal mucosa. Because COX-2 expression is low to undetectable in normal colorectal mucosa, 14 unpaired adenomas were examined for COX-2 expression; a clearly detectable transcript was identified in six (43{\%}). Conclusions: COX-2, but not COX-1, gene expression is markedly elevated in most human colorectal cancers compared with accompanying normal mucosa. Furthermore, COX-2 expression seems to be increased in a subset of adenomas. COX-2 may provide an attractive therapeutic target in colorectal neoplasia.",
author = "Eberhart, {Charles E.} and Coffey, {Robert J.} and Aramandla Radhika and Giardiello, {Francis M} and Suzanne Ferrenbach and Dubois, {Raymond N.}",
year = "1994",
language = "English (US)",
volume = "107",
pages = "1183--1188",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

AU - Eberhart, Charles E.

AU - Coffey, Robert J.

AU - Radhika, Aramandla

AU - Giardiello, Francis M

AU - Ferrenbach, Suzanne

AU - Dubois, Raymond N.

PY - 1994

Y1 - 1994

N2 - Background/Aims: Several clinical, epidemiological, and animal studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) may alter the incidence of colorectal cancer. A likely target for NSAIDs is cyclooxygenase, a key enzyme in arachidonic acid metabolism. Two isoforms of this enzyme have been identified; cyclooxygenase (COX) 1 and COX-2. The present study was undertaken to determine if there is differential expression of these isoforms in colorectal neoplasia, and, if so, at what stage in malignant transformation this occurs. Methods: COX-1 and COX-2 messenger RNA (mRNA) levels were determined by Northern blot analysis of poly(A) + RNA isolated from human colorectal cancers, adenomas, and accompanying normal mucosa. Results: There was a marked increase in COX-2 mRNA levels in 12 of 14 carcinomas (86%) compared with paired normal mucosa. In contrast, there was equivalent intensity of the COX-1 mRNA transcript between the normal mucosa and cancer in all 14 cases. In six pairs of colorectal adenomas and normal mucosa, three showed up-regulation of COX-2 in the adenoma compared with the normal mucosa. Because COX-2 expression is low to undetectable in normal colorectal mucosa, 14 unpaired adenomas were examined for COX-2 expression; a clearly detectable transcript was identified in six (43%). Conclusions: COX-2, but not COX-1, gene expression is markedly elevated in most human colorectal cancers compared with accompanying normal mucosa. Furthermore, COX-2 expression seems to be increased in a subset of adenomas. COX-2 may provide an attractive therapeutic target in colorectal neoplasia.

AB - Background/Aims: Several clinical, epidemiological, and animal studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) may alter the incidence of colorectal cancer. A likely target for NSAIDs is cyclooxygenase, a key enzyme in arachidonic acid metabolism. Two isoforms of this enzyme have been identified; cyclooxygenase (COX) 1 and COX-2. The present study was undertaken to determine if there is differential expression of these isoforms in colorectal neoplasia, and, if so, at what stage in malignant transformation this occurs. Methods: COX-1 and COX-2 messenger RNA (mRNA) levels were determined by Northern blot analysis of poly(A) + RNA isolated from human colorectal cancers, adenomas, and accompanying normal mucosa. Results: There was a marked increase in COX-2 mRNA levels in 12 of 14 carcinomas (86%) compared with paired normal mucosa. In contrast, there was equivalent intensity of the COX-1 mRNA transcript between the normal mucosa and cancer in all 14 cases. In six pairs of colorectal adenomas and normal mucosa, three showed up-regulation of COX-2 in the adenoma compared with the normal mucosa. Because COX-2 expression is low to undetectable in normal colorectal mucosa, 14 unpaired adenomas were examined for COX-2 expression; a clearly detectable transcript was identified in six (43%). Conclusions: COX-2, but not COX-1, gene expression is markedly elevated in most human colorectal cancers compared with accompanying normal mucosa. Furthermore, COX-2 expression seems to be increased in a subset of adenomas. COX-2 may provide an attractive therapeutic target in colorectal neoplasia.

UR - http://www.scopus.com/inward/record.url?scp=0027993458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027993458&partnerID=8YFLogxK

M3 - Article

C2 - 7926468

AN - SCOPUS:0027993458

VL - 107

SP - 1183

EP - 1188

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -